Search
PTC Therapeutics Inc
PTCTAdd to Watchlist
68.970USD
+0.850+1.25%
Close 11-04 16:00（ET）
5.76BMarket Cap
LossP/E TTM
Today
+1.25%
5 Days
+9.44%
1 Month
+8.68%
6 Months
+5.31%
Year to Date
-9.20%
1 Year
+1.85%
Key Figures
69.680Open
70.110High
210.92KVolume
LossP/E TTM
23.43P/E Dynamic
--Dividend TTM
0.25%Turnover Ratio
68.120Prev. Close
66.870Low
14.51MTurnover
LossP/E Static
-30.11P/B
0.00%Div Yield TTM
-6.76%ROA
90.87052wk High
46.88Volume Ratio
-363.30MNet Profit
83.54MShares
-2.5443EPS TTM
0.54Beta
--ROE
58.80052wk Low
9.62%Amplitude
89.14%Gross Margin
5.76BMarket Cap
-3.91Reward/Risk
2.70%Risk Rate
PTC Therapeutics Inc's Score
0.15vs previous score
Forecast8.40
Financial Health7.49
Technical5.13
Valuation Dimensions9.60
Institutional Confidence10.00
Risk Assessment6.89
Media Coverage
Coverage Level
Very Low
Very High
No data
Analyst Rating
PTC Therapeutics Inc Technical Analysis
Technical Indicators
Buy
Summary
Buy
Moving Average
Buy
PTC Therapeutics Inc Latest Earnings Call Transcripts
PTC Therapeutics (PTCT) Q3 2026 Earnings Call: Suffiance Drives Guidance Increase
PTC Therapeutics Q3 2026 revenue reached $358 million as Suffiance generated $182 million. The company raised full-year guidance and detailed ST920 plans.
Financial Indicators
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
Earnings
Next reporting date
--
Reporting Period
2026Q3
Earnings / Forecast
-0.62/0.34
Revenue / Forecast
357.81M/306.40M
PTC Therapeutics Inc Profile
SectorPharmaceuticals
Ticker SymbolPTCT
Number of employees939
CountryUnited States of America
Ownership
| Shareholders | Proportion |
|---|---|
| BlackRock Institutional Trust Company, N.A. | 13.72% |
| RTW Investments L.P. | 9.34% |
| Janus Henderson Investors | 5.85% |
| Vanguard Portfolio Management, LLC | 5.79% |
| Shareholder Types | Proportion |
|---|---|
| Investment Advisor/Hedge Fund | 44.49% |
| Investment Advisor | 43.10% |
| Hedge Fund | 13.82% |
| Research Firm | 11.91% |
Related Instruments
+0.61%
+3.81%
+3.09%
+3.93%
+3.59%
+2.79%
+3.73%
+4.19%
+4.95%
+2.63%
+3.44%
+4.02%
+6.98%
+4.72%
+13.11%
+5.03%
-4.39%
+1.49%
+3.55%
+3.36%Popular Instruments
53522.400
+157.800 (+0.30%)
28111.200
-322.700 (-1.14%)
7670.800
-21.600 (-0.28%)
12797.000
-1.000 (-0.01%)
61135.000
-1886.000 (-2.99%)
6280.500
-25.400 (-0.40%)
86.605
-1.436 (-1.63%)
349.510
+17.610 (+5.31%)
200.130
-6.560 (-3.17%)
4122.960
+59.020 (+1.45%)
FAQs
What is the current price of PTC Therapeutics Inc (PTCT)?
The current price of PTC Therapeutics Inc (PTCT) is 68.97.
What is the symbol of PTC Therapeutics Inc?
The ticker symbol of PTC Therapeutics Inc is PTCT.
What is the 52-week high of PTC Therapeutics Inc?
The 52-week high of PTC Therapeutics Inc is 90.87.
What is the 52-week low of PTC Therapeutics Inc?
The 52-week low of PTC Therapeutics Inc is 58.80.
What is the market capitalization of PTC Therapeutics Inc?
The market capitalization of PTC Therapeutics Inc is 5.76B.
Is PTC Therapeutics Inc (PTCT) currently rated as Buy, Hold, or Sell?
According to analysts, PTC Therapeutics Inc (PTCT) has an overall rating of Buy, with a price target of 98.40.
What is the Earnings Per Share (EPS TTM) of PTC Therapeutics Inc (PTCT)?
The Earnings Per Share (EPS TTM) of PTC Therapeutics Inc (PTCT) is -2.54.